| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The BATTLE trial: personalizing therapy for lung cancer.
|
Cancer Discov
|
2011
|
7.57
|
|
2
|
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.
|
Int J Radiat Oncol Biol Phys
|
2002
|
6.82
|
|
3
|
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
|
J Clin Oncol
|
2012
|
4.77
|
|
4
|
Dose escalation methods in phase I cancer clinical trials.
|
J Natl Cancer Inst
|
2009
|
4.36
|
|
5
|
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
|
Clin Cancer Res
|
2012
|
3.48
|
|
6
|
Retracted
The influence of resection and aneuploidy on mortality in oral leukoplakia.
|
N Engl J Med
|
2004
|
3.22
|
|
7
|
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.
|
J Clin Oncol
|
2008
|
3.16
|
|
8
|
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
|
J Clin Oncol
|
2012
|
3.08
|
|
9
|
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer.
|
Cancer Prev Res (Phila)
|
2012
|
3.03
|
|
10
|
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
|
Clin Trials
|
2009
|
2.79
|
|
11
|
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
|
J Natl Cancer Inst
|
2012
|
2.79
|
|
12
|
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
|
Clin Trials
|
2008
|
2.71
|
|
13
|
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
|
J Natl Cancer Inst
|
2006
|
2.61
|
|
14
|
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
|
Clin Cancer Res
|
2010
|
2.56
|
|
15
|
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance.
|
Int J Radiat Oncol Biol Phys
|
2012
|
2.55
|
|
16
|
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
|
J Clin Oncol
|
2002
|
2.52
|
|
17
|
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.
|
J Clin Oncol
|
2012
|
2.48
|
|
18
|
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
2.48
|
|
19
|
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.
|
J Clin Oncol
|
2007
|
2.40
|
|
20
|
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
2.31
|
|
21
|
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
|
Cancer Res
|
2012
|
2.27
|
|
22
|
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
|
Clin Cancer Res
|
2006
|
2.24
|
|
23
|
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.
|
J Clin Oncol
|
2009
|
2.15
|
|
24
|
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome.
|
Cancer
|
2006
|
2.04
|
|
25
|
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.
|
Cancer Prev Res (Phila)
|
2009
|
1.99
|
|
26
|
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
|
PLoS One
|
2011
|
1.80
|
|
27
|
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.
|
Cancer Prev Res (Phila)
|
2010
|
1.80
|
|
28
|
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene.
|
J Natl Cancer Inst
|
2007
|
1.79
|
|
29
|
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial.
|
J Natl Cancer Inst
|
2003
|
1.75
|
|
30
|
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
|
J Clin Oncol
|
2009
|
1.74
|
|
31
|
Mortality risk from squamous cell skin cancer.
|
J Clin Oncol
|
2005
|
1.74
|
|
32
|
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system.
|
Cancer Prev Res (Phila)
|
2009
|
1.71
|
|
33
|
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.
|
Cancer Prev Res (Phila)
|
2011
|
1.70
|
|
34
|
Objective detection and delineation of oral neoplasia using autofluorescence imaging.
|
Cancer Prev Res (Phila)
|
2009
|
1.66
|
|
35
|
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.
|
J Clin Oncol
|
2009
|
1.66
|
|
36
|
Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy.
|
Cancer
|
2009
|
1.61
|
|
37
|
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types.
|
Carcinogenesis
|
2005
|
1.61
|
|
38
|
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.
|
J Clin Oncol
|
2007
|
1.61
|
|
39
|
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.
|
Clin Cancer Res
|
2009
|
1.60
|
|
40
|
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.
|
J Natl Cancer Inst
|
2010
|
1.59
|
|
41
|
High-dose fenretinide in oral leukoplakia.
|
Cancer Prev Res (Phila)
|
2009
|
1.59
|
|
42
|
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.
|
J Natl Cancer Inst
|
2007
|
1.58
|
|
43
|
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants.
|
Cancer Prev Res (Phila)
|
2009
|
1.57
|
|
44
|
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
|
J Clin Oncol
|
2005
|
1.54
|
|
45
|
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer.
|
Clin Cancer Res
|
2008
|
1.50
|
|
46
|
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.
|
J Clin Oncol
|
2002
|
1.50
|
|
47
|
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions.
|
Cancer
|
2006
|
1.45
|
|
48
|
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States).
|
Cancer Causes Control
|
2003
|
1.39
|
|
49
|
Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.
|
Cancer
|
2006
|
1.36
|
|
50
|
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.
|
Clin Cancer Res
|
2011
|
1.33
|
|
51
|
Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia.
|
Cancer Prev Res (Phila)
|
2012
|
1.33
|
|
52
|
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
|
Clin Cancer Res
|
2003
|
1.32
|
|
53
|
Genetic variation in MicroRNA genes and risk of oral premalignant lesions.
|
Mol Carcinog
|
2010
|
1.32
|
|
54
|
Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs.
|
Cancer Prev Res (Phila)
|
2008
|
1.32
|
|
55
|
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
|
Cancer Res
|
2012
|
1.32
|
|
56
|
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
|
Mol Cancer Ther
|
2007
|
1.29
|
|
57
|
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
|
J Thorac Oncol
|
2012
|
1.28
|
|
58
|
A generalized response surface model with varying relative potency for assessing drug interaction.
|
Biometrics
|
2006
|
1.28
|
|
59
|
Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck.
|
Laryngoscope
|
2005
|
1.27
|
|
60
|
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
|
Oncotarget
|
2013
|
1.26
|
|
61
|
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy.
|
J Clin Oncol
|
2008
|
1.25
|
|
62
|
Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer.
|
Cancer Res
|
2006
|
1.24
|
|
63
|
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
|
Clin Cancer Res
|
2008
|
1.23
|
|
64
|
Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers.
|
Cancer Res
|
2002
|
1.22
|
|
65
|
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
|
Cancer
|
2008
|
1.21
|
|
66
|
A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.
|
Clin Cancer Res
|
2010
|
1.21
|
|
67
|
A simulation study for comparing testing statistics in response-adaptive randomization.
|
BMC Med Res Methodol
|
2010
|
1.20
|
|
68
|
Akt activation correlates with adverse outcome in tongue cancer.
|
Cancer
|
2005
|
1.20
|
|
69
|
Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome.
|
Cancer
|
2011
|
1.18
|
|
70
|
Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.
|
J Clin Oncol
|
2004
|
1.18
|
|
71
|
Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry.
|
Cancer Res
|
2006
|
1.17
|
|
72
|
Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies.
|
Cancer
|
2004
|
1.16
|
|
73
|
Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
|
Cancer Prev Res (Phila)
|
2010
|
1.15
|
|
74
|
Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development.
|
Cancer Res
|
2009
|
1.15
|
|
75
|
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
|
Clin Cancer Res
|
2013
|
1.14
|
|
76
|
Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions.
|
Carcinogenesis
|
2006
|
1.14
|
|
77
|
Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers.
|
Cancer Prev Res (Phila)
|
2008
|
1.13
|
|
78
|
Gene expression profiling predicts the development of oral cancer.
|
Cancer Prev Res (Phila)
|
2011
|
1.13
|
|
79
|
Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer.
|
Cancer
|
2011
|
1.12
|
|
80
|
Tissue platinum concentration and tumor response in non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
1.11
|
|
81
|
DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy.
|
Clin Cancer Res
|
2011
|
1.08
|
|
82
|
Nucleotide excision repair pathway genes and oral premalignant lesions.
|
Clin Cancer Res
|
2007
|
1.08
|
|
83
|
Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.
|
Ann Surg Oncol
|
2009
|
1.08
|
|
84
|
A semiparametric response surface model for assessing drug interaction.
|
Biometrics
|
2007
|
1.07
|
|
85
|
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
|
J Thorac Oncol
|
2012
|
1.06
|
|
86
|
Fenretinide activity in retinoid-resistant oral leukoplakia.
|
Clin Cancer Res
|
2006
|
1.06
|
|
87
|
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.
|
Cancer Res
|
2011
|
1.05
|
|
88
|
Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis.
|
Clin Cancer Res
|
2004
|
1.05
|
|
89
|
GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells.
|
Cancer Res
|
2002
|
1.05
|
|
90
|
A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors.
|
PLoS One
|
2009
|
1.03
|
|
91
|
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
|
Mol Cancer Ther
|
2010
|
1.03
|
|
92
|
The BATTLE to personalize lung cancer prevention through reverse migration.
|
Cancer Prev Res (Phila)
|
2011
|
1.02
|
|
93
|
MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.
|
Carcinogenesis
|
2010
|
1.01
|
|
94
|
Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
|
PLoS One
|
2011
|
1.00
|
|
95
|
The cost of prostate cancer chemoprevention: a decision analysis model.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
1.00
|
|
96
|
Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer.
|
J Natl Cancer Inst
|
2003
|
1.00
|
|
97
|
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.
|
PLoS One
|
2012
|
1.00
|
|
98
|
Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
|
Clin Cancer Res
|
2004
|
1.00
|
|
99
|
Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression.
|
Clin Cancer Res
|
2007
|
0.99
|
|
100
|
The risk of second primary tumors after resection of stage I nonsmall cell lung cancer.
|
Ann Thorac Surg
|
2003
|
0.99
|
|
101
|
Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.
|
J Thorac Oncol
|
2015
|
0.99
|
|
102
|
Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions.
|
Clin Cancer Res
|
2009
|
0.99
|
|
103
|
Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
|
Cancer Res
|
2006
|
0.98
|
|
104
|
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia.
|
Clin Cancer Res
|
2009
|
0.97
|
|
105
|
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.
|
Clin Cancer Res
|
2006
|
0.97
|
|
106
|
Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.
|
J Thorac Oncol
|
2013
|
0.96
|
|
107
|
Demystify statistical significance--time to move on from the p value to bayesian analysis.
|
J Natl Cancer Inst
|
2010
|
0.96
|
|
108
|
Phase II trial design with Bayesian adaptive randomization and predictive probability.
|
J R Stat Soc Ser C Appl Stat
|
2012
|
0.95
|
|
109
|
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
|
Clin Cancer Res
|
2013
|
0.95
|
|
110
|
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
|
J Clin Oncol
|
2006
|
0.94
|
|
111
|
Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.93
|
|
112
|
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
|
Cancer
|
2012
|
0.92
|
|
113
|
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
|
J Thorac Oncol
|
2013
|
0.92
|
|
114
|
Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.
|
Cancer Prev Res (Phila)
|
2012
|
0.92
|
|
115
|
Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial.
|
BMC Cancer
|
2011
|
0.91
|
|
116
|
Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy.
|
Clin Cancer Res
|
2013
|
0.91
|
|
117
|
Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification.
|
Oncogene
|
2002
|
0.91
|
|
118
|
Epidemiology of head and neck squamous cell cancer among HIV-infected patients.
|
J Acquir Immune Defic Syndr
|
2014
|
0.90
|
|
119
|
Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
|
Contemp Clin Trials
|
2013
|
0.90
|
|
120
|
Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia.
|
J Biomed Opt
|
2011
|
0.88
|
|
121
|
Cyclin D1 and cancer development in laryngeal premalignancy patients.
|
Cancer Prev Res (Phila)
|
2009
|
0.87
|
|
122
|
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
|
Mol Cancer Ther
|
2013
|
0.87
|
|
123
|
G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.86
|
|
124
|
Tetranucleotide microsatellite instability in surgical margins for prediction of local recurrence of head and neck squamous cell carcinoma.
|
Clin Cancer Res
|
2004
|
0.86
|
|
125
|
Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.85
|
|
126
|
Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers.
|
J Clin Oncol
|
2005
|
0.85
|
|
127
|
Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma.
|
Carcinogenesis
|
2010
|
0.85
|
|
128
|
Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
|
Clin Cancer Res
|
2003
|
0.85
|
|
129
|
Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions.
|
Cancer Res
|
2002
|
0.85
|
|
130
|
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
|
Cancer
|
2002
|
0.85
|
|
131
|
Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis.
|
Cancer
|
2005
|
0.84
|
|
132
|
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
|
Mol Cancer Ther
|
2013
|
0.84
|
|
133
|
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
|
J Thorac Oncol
|
2012
|
0.84
|
|
134
|
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.
|
Clin Cancer Res
|
2012
|
0.84
|
|
135
|
Phase II study of gefitinib in patients with advanced salivary gland cancers.
|
Head Neck
|
2015
|
0.83
|
|
136
|
Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions.
|
Cancer
|
2009
|
0.83
|
|
137
|
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
|
J Thorac Oncol
|
2011
|
0.82
|
|
138
|
Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma.
|
Cancer
|
2013
|
0.82
|
|
139
|
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
|
Cancer
|
2010
|
0.82
|
|
140
|
Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer.
|
Clin Lung Cancer
|
2011
|
0.82
|
|
141
|
Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication.
|
Clin Cancer Res
|
2004
|
0.82
|
|
142
|
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.
|
Clin Lung Cancer
|
2006
|
0.82
|
|
143
|
Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development.
|
Endocrinology
|
2011
|
0.82
|
|
144
|
Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer.
|
Int J Oncol
|
2012
|
0.80
|
|
145
|
Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy.
|
Cancer Prev Res (Phila)
|
2011
|
0.80
|
|
146
|
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
|
J Thorac Oncol
|
2013
|
0.79
|
|
147
|
Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs.
|
Stat Med
|
2014
|
0.79
|
|
148
|
Estimation of k for the poly-k test with application to animal carcinogenicity studies.
|
Stat Med
|
2003
|
0.79
|
|
149
|
Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions.
|
Cancer
|
2008
|
0.79
|
|
150
|
Accelerated approval and breakthrough therapy designation: oncology drug development on speed?
|
Clin Cancer Res
|
2013
|
0.79
|
|
151
|
Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers.
|
J Natl Cancer Inst
|
2003
|
0.78
|
|
152
|
Applying Emax model and bivariate thin plate splines to assess drug interactions.
|
Front Biosci (Elite Ed)
|
2010
|
0.78
|
|
153
|
Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.
|
Technol Cancer Res Treat
|
2009
|
0.78
|
|
154
|
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.
|
Am J Clin Oncol
|
2009
|
0.77
|
|
155
|
Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
0.77
|
|
156
|
9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers.
|
Clin Cancer Res
|
2005
|
0.77
|
|
157
|
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
|
Am J Clin Oncol
|
2010
|
0.77
|
|
158
|
Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.76
|
|
159
|
Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer.
|
Exp Ther Med
|
2010
|
0.76
|
|
160
|
Reply to A. Levy et al.
|
J Clin Oncol
|
2013
|
0.75
|
|
161
|
RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
|
J Natl Cancer Inst
|
2013
|
0.75
|
|
162
|
Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method.
|
Contemp Clin Trials
|
2013
|
0.75
|
|
163
|
Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention.
|
Cancer Prev Res (Phila)
|
2010
|
0.75
|
|
164
|
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
|
Clin Lung Cancer
|
2003
|
0.75
|